Marwan Sabbagh, MD
Neurology · Phoenix, AZNPI 1497748289
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $415,547 of the $603,067 with a category attached, or 68.9%. 34 manufacturers reported payments, led by Eisai Inc. at 24.5% of the total. Among neurology clinicians in AZ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 404 payments — averaging $1492.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eisai Inc.$148K
- Biogen$60K
- Acadia Pharmaceuticals Inc$56K
- F. Hoffmann-la Roche AG$49K
- Lilly USA, LLC$48K
- Novo Nordisk AS$40K
- plus $202K from 28 others
Across 10 payments — averaging $35,552 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$345K
- Novo Nordisk AS$5K
- AbbVie$4K
- F. Hoffmann-la Roche AG$1K
- Biogen$876
What the payments were for
- Consulting fees$415,54769%
- Speaking & faculty fees$93,01115%
- Travel & lodging$86,36114%
- Food & beverage$7,1091%
- Education$1,0390%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eisai Inc. | 127 | $148,020 |
| Biogen | 40 | $60,460 |
| Acadia Pharmaceuticals Inc | 37 | $56,426 |
| F. Hoffmann-la Roche AG | 16 | $48,553 |
| Lilly USA, LLC | 37 | $48,017 |
| Novo Nordisk AS | 20 | $39,680 |
| Eli Lilly | 14 | $34,067 |
| Eisai CO., LTD. | 8 | $33,279 |
| Genentech USA, Inc. | 15 | $27,105 |
| Novo Nordisk | 13 | $21,963 |
| Genentech, Inc. | 11 | $15,027 |
| Roche Diagnostics Corporation | 7 | $12,382 |
| AbbVie(2 entities) | 9 | $11,168 |
| Janssen Global Services, LLC | 8 | $9,199 |
| Regeneron | 7 | $6,318 |
| Otsuka America Pharmaceutical, Inc. | 2 | $5,550 |
| Roche Diagnostics International Ltd | 2 | $4,890 |
| Corium, LLC | 2 | $4,058 |
| Merck | 1 | $3,375 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 4 | $3,295 |
| Beckman Coulter, Inc. | 2 | $2,750 |
| Lundbeck LLC | 4 | $2,152 |
| GE HealthCare | 3 | $2,028 |
| GSK | 2 | $1,788 |
| Roche Products Limited | 1 | $1,035 |
| Axsome Therapeutics, Inc. | 2 | $201 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $63 |
| C2n Diagnostics, LLC | 1 | $59 |
| Amgen | 1 | $39 |
| Grifols Shared Services North America, Inc. | 1 | $32 |
| Life Molecular Imaging Ltd | 1 | $28 |
| E.r. Squibb & Sons, L.L.C. | 1 | $28 |
| Avanir Pharmaceuticals, Inc. | 1 | $19 |
| Catalyst Pharmaceuticals, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$603,067 in reported general payments places this provider in the 95th percentile of 388 neurology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NuplazidPimavanserin Tartrate | 21 | $105,688 |
| RexultiBrexpiprazole | 13 | $28,874 |
| Memantine Hcl | 338 | $14,723 |
| Galantamine Hbr | 150 | $11,162 |
| Rivastigmine | 45 | $6,894 |
| Donepezil Hcl | 283 | $3,668 |
| Quetiapine Fumarate | 96 | $3,070 |
| Galantamine ErGalantamine Hbr | 25 | $2,951 |
| RivastigmineRivastigmine Tartrate | 36 | $2,695 |
| Sertraline Hcl | 104 | $2,474 |
| Citalopram HbrCitalopram Hydrobromide | 104 | $2,119 |
| Mirtazapine | 96 | $1,707 |
| Duloxetine Hcl | 25 | $890 |
| Escitalopram Oxalate | 62 | $702 |
| Levetiracetam | 11 | $567 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Acadia Pharmaceuticals IncNuplazid | $56,426 | $105,68821 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $5,550 | $28,87413 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 388 neurology providers in Arizona.
Other neurology in Phoenix
- Barry HendinPhoenix$2.3M
- Maria OspinaPhoenix$2.1M
- Suraj MuleyPhoenix$1.7M
- Eric ErossPhoenix$778K
- Steve ChungPhoenix$685K
- Kerry KnievelPhoenix$509K
- Lori TravisPhoenix$406K
- Jeffrey GittPhoenix$275K
- Todd SchwedtPhoenix$273K
- Joshua TobinPhoenix$234K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.